세계의 오피오이드 사용 장애(OUD) 시장 보고서 : 동향, 예측 및 경쟁 분석(-2030년)

Opioid Use Disorder (OUD) Trends and Forecast

The future of the global opioid use disorder (OUD) market looks promising with opportunities in the hospital pharmacy and retail pharmacy markets. The global opioid use disorder (OUD) market is expected to reach an estimated $7.2 billion by 2030 with a CAGR of 10.3% from 2024 to 2030. The major drivers for this market are the growing prevalence of chronic diseases, such as cancer, cardiovascular diseases, and orthopedic diseases, and the increasing recognition of buprenorphine patches as an efficient treatment option.

• Lucintel forecasts that, within the drug type category, agonists will remain the larger segment over the forecast period due to the growing aging population and increase in the prevalence of opioid abuse.
• Within the distribution channel category, hospital pharmacies will remain the larger segment due to rising expenditure by the government to develop healthcare infrastructure.
• In terms of regions, North America will remain the largest region over the forecast period due to a rise in the number of product launches and product approval for opioid use disorder.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Opioid Use Disorder (OUD) Market

Emerging trends in the opioid use disorder (OUD) market are shaping the future of treatment with advancements in medication, technology, and holistic approaches. These trends reflect a shift towards more comprehensive and personalized care strategies.

• Increased Use of Digital Health Technologies: Digital health technologies

s, including telemedicine and mobile health apps, are being increasingly integrated into OUD treatment plans. These tools provide remote monitoring, virtual counseling, and personalized treatment adjustments, improving patient engagement and access to care.

• Advancements in Medication-Assisted Treatment (MAT): There have been significant innovations in MAT, including extended-release formulations and novel combination therapies. These advancements enhance treatment adherence and reduce the potential for misuse, offering more effective and long-lasting solutions for managing OUD.
• Focus on Integrated Care Models: Integrated care models that combine OUD treatment with mental health and social support services are gaining traction. This holistic approach addresses the multifaceted needs of patients, improving overall outcomes and reducing the risk of relapse.
• Expansion of Harm Reduction Programs: Harm reduction strategies, such as needle exchange programs and supervised consumption sites, are being expanded. These programs aim to reduce the negative health consequences of drug use and provide pathways to treatment and recovery.
• Emphasis on Personalized Medicine: Personalized medicine approaches, including genetic testing and individualized treatment plans, are becoming more prevalent. These strategies tailor treatment to the specific needs and characteristics of each patient, improving efficacy and minimizing side effects.

These emerging trends are reshaping the OUD market by introducing more effective, personalized, and integrated approaches to treatment. The focus on digital health, advanced medications, and holistic care models reflects a shift towards improving patient outcomes and addressing the complex needs of those affected by opioid use disorder.

Recent Developments in the Opioid Use Disorder (OUD) Market

Recent developments in the opioid use disorder (OUD) market have focused on improving treatment options, expanding access, and enhancing support systems. These changes are driven by the ongoing need to address the opioid crisis and provide effective, comprehensive care.

• Expansion of Medication-Assisted Treatment (MAT): New MAT formulations and extended-release options have been introduced, improving treatment adherence and efficacy. Innovations in buprenorphine and naltrexone formulations offer better management of withdrawal symptoms and relapse prevention.
• Integration of Digital Tools: The adoption of digital health tools, including telemedicine platforms and mobile apps, has enhanced the delivery of OUD treatment. These tools facilitate remote monitoring, virtual counseling, and data-driven adjustments to treatment plans.
• Strengthening Harm Reduction Initiatives: Governments and organizations have increased funding and support for harm reduction programs. Needle exchange programs, supervised consumption sites, and naloxone distribution efforts are expanding, aiming to reduce the negative impact of opioid use.
• Policy and Regulatory Changes: New regulations and policies have been implemented to improve access to OUD treatments and support services. Policies include expanded insurance coverage for MAT and initiatives to reduce stigma and increase public awareness.
• Focus on Integrated Care Models: Integrated care models that combine OUD treatment with mental health and social support services are being promoted. These models address the comprehensive needs of patients and enhance overall treatment effectiveness.

These recent developments reflect a concerted effort to improve OUD treatment and support systems. By focusing on medication advancements, digital tools, harm reduction, policy changes, and integrated care, the market is evolving to better address the complexities of opioid use disorder and support patient recovery.

Strategic Growth Opportunities for Opioid Use Disorder (OUD) Market

The opioid use disorder (OUD) market presents several strategic growth opportunities across various applications. Leveraging these opportunities can enhance treatment outcomes, expand access, and address the ongoing opioid crisis effectively.

• Expansion of MAT Programs: Expanding medication-assisted treatment programs to underserved areas offers significant growth potential. Increasing the availability of MAT options, such as buprenorphine and methadone, can improve access to effective treatment for those struggling with OUD.
• Integration of Digital Health Solutions: The incorporation of digital health solutions, including telemedicine and mobile apps, provides growth opportunities. These tools enhance treatment delivery, patient engagement, and monitoring, creating new avenues for market expansion.
• Development of Novel Therapies: Investing in research and development of novel therapies, such as new drug formulations and combination treatments, presents growth opportunities. Innovative therapies that address unmet needs can capture market share and offer improved treatment options.
• Expansion of Harm Reduction Programs: Expanding harm reduction programs, such as needle exchange services and supervised consumption sites, offers growth opportunities. These programs can reduce the impact of opioid use and provide pathways to treatment and recovery.
• Enhancement of Integrated Care Models: Developing and implementing integrated care models that combine OUD treatment with mental health and social support services presents growth potential. These models improve patient outcomes and address the multifaceted needs of individuals with OUD.

Strategic growth opportunities in the OUD market include expanding MAT programs, integrating digital health solutions, developing novel therapies, scaling harm reduction initiatives, and enhancing integrated care models. These opportunities align with the evolving needs of the market and can drive significant improvements in treatment and recovery outcomes.

Opioid Use Disorder (OUD) Market Driver and Challenges

The opioid use disorder (OUD) market is significantly influenced by various drivers and challenges that encompass technological advancements, economic factors, and regulatory changes. The drivers include innovations in treatment options, increased awareness, policy reforms, economic incentives, and improved access to care. Challenges, on the other hand, involve regulatory hurdles, economic barriers, and issues related to treatment adherence and accessibility. Understanding these factors is crucial for stakeholders aiming to navigate the complexities of the OUD market and enhance strategies for effective treatment and management.

The factors responsible for driving the opioid use disorder (OUD) market include:

1. Technological Advancements: Innovations in treatment technologies, such as digital health tools and advanced medication formulations, are driving growth in the OUD market. Digital platforms facilitate remote monitoring, telemedicine, and personalized treatment plans, improving patient engagement and outcomes. New drug formulations, including extended-release options, enhance the efficacy and convenience of treatment, contributing to increased market demand.

2. Increased Awareness and Education: Growing awareness about the opioid crisis and OUD has led to increased demand for effective treatments. Educational campaigns and public health initiatives are improving understanding of opioid addiction, reducing stigma, and encouraging individuals to seek treatment. This heightened awareness is driving market growth as more people recognize the need for OUD management solutions.

3. Policy and Regulatory Reforms: Changes in policies and regulations are facilitating better access to OUD treatments. Government initiatives, such as expanded insurance coverage for medication-assisted treatment (MAT) and supportive legislation, are reducing barriers to care. These reforms are encouraging healthcare providers to offer a wider range of treatment options and improving overall access for patients.

4. Economic Incentives and Funding: Increased funding from government and private sources is supporting OUD treatment programs and research. Economic incentives, such as subsidies for MAT and grants for addiction treatment facilities, are making it easier for providers to offer comprehensive care. This financial support is driving market growth by enhancing treatment availability and innovation.

5. Expansion of Treatment Access: Efforts to expand access to OUD treatments, particularly in underserved and rural areas, are driving market growth. Initiatives to increase the number of treatment centers, provide mobile treatment units, and integrate care into primary health services are improving accessibility. These efforts are ensuring that more individuals can receive the necessary care for managing OUD.

Challenges in the opioid use disorder (OUD) market include:

1. Regulatory Hurdles: Navigating complex regulatory requirements and obtaining approvals for new treatments can be challenging. Variability in regulations across regions can delay market entry for innovative therapies and create barriers to widespread adoption. Compliance with stringent guidelines can also increase costs for manufacturers and limit treatment availability.

2. Economic Barriers: High costs associated with OUD treatments, including medications and therapy programs, can be a significant barrier. Economic constraints may limit patient access to necessary care and affect treatment adherence. Insufficient insurance coverage and out-of-pocket expenses can further exacerbate these challenges, impacting overall market growth.

3. Treatment Adherence and Accessibility Issues: Ensuring consistent treatment adherence and addressing accessibility issues pose significant challenges. Patients may struggle with adherence due to side effects, stigma, or lack of support. Limited availability of treatment centers, particularly in remote areas, can also hinder access and affect the effectiveness of OUD management efforts.

The opioid use disorder market is shaped by a complex interplay of drivers and challenges. Technological advancements, increased awareness, policy reforms, economic incentives, and expanded access are key drivers that enhance treatment effectiveness and availability. However, regulatory hurdles, economic barriers, and issues with treatment adherence and accessibility present significant challenges. Addressing these factors is crucial for optimizing market strategies and improving outcomes for individuals affected by opioid use disorder. Understanding and navigating these dynamics will be essential for stakeholders seeking to advance the OUD treatment landscape.

List of Opioid Use Disorder (OUD) Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies opioid use disorder (OUD) companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the opioid use disorder (OUD) companies profiled in this report include-

• Hikma Pharmaceuticals
• Indivior
• Titan Pharmaceuticals
• Reckitt Benckiser Pharmaceuticals
• Camurus
• BioDelivery Sciences International
• Sandoz

Opioid Use Disorder (OUD) by Segment

The study includes a forecast for the global opioid use disorder (OUD) by drug type, age group, route of administration, distribution channel, and region.

Opioid Use Disorder (OUD) Market by Drug Type [Analysis by Value from 2018 to 2030]:

• Agonist
• Antagonist

Opioid Use Disorder (OUD) Market by Age Group [Analysis by Value from 2018 to 2030]:

• 19 To 39
• 40 To 59
• Age 60 and Over

List of Opioid Use Disorder (OUD) Companies

Opioid Use Disorder (OUD) Market by Route of Administration [Analysis by Value from 2018 to 2030]:

• Oral
• Intravenous
• Sublingual

Opioid Use Disorder (OUD) Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific

Opioid Use Disorder (OUD) Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

• Hospital Pharmacy
• Retail Pharmacy

Country Wise Outlook for the Opioid Use Disorder (OUD) Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. Below is a summary of recent developments by major opioid use disorder producers in key regions: the USA, China, India, Japan, and Germany.

• United States: In the US, there has been a notable increase in the availability of naloxone and buprenorphine, with expanded access through recent legislation. The FDA approved new formulations of buprenorphine for enhanced efficacy and ease of use. Additionally, federal and state governments are implementing comprehensive strategies, including expanded treatment facilities and harm reduction programs.
• China: China has been focusing on improving access to opioid dependence treatments, including methadone maintenance therapy (MMT) and buprenorphine. Recent policy changes have aimed to integrate OUD treatment into broader healthcare services. Efforts to increase public awareness and reduce stigma around addiction are also being emphasized.
• Germany: Germany has advanced its treatment protocols with new guidelines incorporating both pharmacological and psychosocial interventions. The integration of digital health solutions, such as telemedicine for therapy management, has been a key development. Increased funding for addiction treatment services has also been noted.
• India: In India, there is a growing focus on increasing access to OUD treatments, with an emphasis on expanding methadone and buprenorphine programs. Recent developments include the establishment of more treatment centers and community-based programs. Public awareness campaigns are being strengthened to combat stigma and promote treatment options.
• Japan: Japan has introduced new regulations to improve access to opioid treatment programs. There has been an increase in the availability of treatment options such as buprenorphine and extended-release naltrexone. Additionally, efforts to enhance coordination between healthcare providers and support systems have been a focus.

Features of the Global Opioid Use Disorder (OUD) Market

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the opioid use disorder (OUD) market by drug type (agonist and antagonist), age group (19 to 39, 40 to 59, and age 60 and over), route of administration (oral, intravenous, and sublingual), distribution channel (hospital pharmacy and retail pharmacy), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Opioid Use Disorder (OUD) Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Opioid Use Disorder (OUD) Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Opioid Use Disorder (OUD) Market by Drug Type
  • 3.3.1: Agonist
  • 3.3.2: Antagonist
• 3.4: Global Opioid Use Disorder (OUD) Market by Age Group
  • 3.4.1: 19 to 39
  • 3.4.2: 40 to 59
  • 3.4.3: Age 60 and over
• 3.5: Global Opioid Use Disorder (OUD) Market by Route of Administration
  • 3.5.1: Oral
  • 3.5.2: Intravenous
  • 3.5.3: Sublingual
• 3.6: Global Opioid Use Disorder (OUD) Market by Distribution Channel
  • 3.6.1: Hospital pharmacy
  • 3.6.2: Retail Pharmacy

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Opioid Use Disorder (OUD) Market by Region
• 4.2: North American Opioid Use Disorder (OUD) Market
  • 4.2.1: North American Market by Drug Type: Agonist and Antagonist
  • 4.2.2: North American Market by Distribution Channel: Hospital pharmacy and Retail Pharmacy
• 4.3: European Opioid Use Disorder (OUD) Market
  • 4.3.1: European Market by Drug Type: Agonist and Antagonist
  • 4.3.2: European Market by Distribution Channel: Hospital pharmacy and Retail Pharmacy
• 4.4: APAC Opioid Use Disorder (OUD) Market
  • 4.4.1: APAC Market by Drug Type: Agonist and Antagonist
  • 4.4.2: APAC Market by Distribution Channel: Hospital pharmacy and Retail Pharmacy
• 4.5: ROW Opioid Use Disorder (OUD) Market
  • 4.5.1: ROW Market by Drug Type: Agonist and Antagonist
  • 4.5.2: ROW Market by Distribution Channel: Hospital pharmacy and Retail Pharmacy

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Opioid Use Disorder (OUD) Market by Drug Type
  • 6.1.2: Growth Opportunities for the Global Opioid Use Disorder (OUD) Market by Age Group
  • 6.1.3: Growth Opportunities for the Global Opioid Use Disorder (OUD) Market by Route of Administration
  • 6.1.4: Growth Opportunities for the Global Opioid Use Disorder (OUD) Market by Distribution Channel
  • 6.1.5: Growth Opportunities for the Global Opioid Use Disorder (OUD) Market by Region
• 6.2: Emerging Trends in the Global Opioid Use Disorder (OUD) Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Opioid Use Disorder (OUD) Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Opioid Use Disorder (OUD) Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Hikma Pharmaceuticals
• 7.2: Indivior
• 7.3: Titan Pharmaceuticals
• 7.4: Reckitt Benckiser Pharmaceuticals
• 7.5: Camurus
• 7.6: BioDelivery Sciences International
• 7.7: Sandoz